Ashwagandha for Stress and Anxiety

Ashwagandha is the most clinically validated adaptogen for the reduction of perceived stress and serum cortisol. The pivotal trial — Chandrasekhar 2012, double-blind, placebo-controlled, 64 adults with a history of chronic stress — documented a 27.9% reduction in morning serum cortisol with 300 mg twice daily of the standardized KSM-66 root extract over 60 days, against only a 7.9% reduction in placebo. Perceived Stress Scale scores fell by 44%, Hamilton Anxiety Scale scores fell by 56.5%, and side effects were indistinguishable from placebo. A subsequent literature of more than a dozen randomized trials has reproduced the cortisol-lowering effect with both KSM-66 (Ixoreal Biomed, 5% withanolide root-only) and Sensoril (Natreon, 10% withanolide full-spectrum root-and-leaf). The proximate mechanism is two-pronged — HPA-axis modulation at the hypothalamic and pituitary level, and direct positive allosteric modulation of the GABA-A receptor by withanolides and the foundational pharmacology established by the Bhattacharya group at Banaras Hindu University. This page walks through the trial evidence, the mechanism, the comparison with conventional anxiolytics, dosing, and the safety profile.

Table of Contents

1. The Chandrasekhar 2012 KSM-66 Trial
2. HPA-Axis Modulation and Cortisol Reduction
3. GABA-A Receptor Modulation (Bhattacharya Foundation)
4. The Sensoril Full-Spectrum Trials
5. Application to Generalized Anxiety Disorder
6. Comparison with SSRIs, Benzodiazepines, and Buspirone
7. Dosing, Extract Type, and Timing
8. Onset of Effect and Duration of Treatment
9. Stacking with L-Theanine, Magnesium, Rhodiola, and Holy Basil
10. Cautions and Contraindications
11. Key Research Papers
12. Connections

The Chandrasekhar 2012 KSM-66 Trial

Chandrasekhar, Kapoor, and Anishetty published their landmark trial in the Indian Journal of Psychological Medicine in 2012 — the study that converted Ashwagandha from a traditional Ayurvedic recommendation into an evidence-based clinical option for stress reduction in the modern integrative medicine literature.

The design was a prospective, randomized, double-blind, placebo-controlled trial. Sixty-four adults aged 18-54 with a history of chronic stress were randomized to receive either 300 mg of KSM-66 root extract twice daily, or matched placebo, for 60 days. The active extract was standardized to contain at least 5% withanolides by HPLC, derived from the root only (no leaf material). Outcome measures included the Perceived Stress Scale (PSS), the General Health Questionnaire (GHQ-28), the Hamilton Anxiety Rating Scale (HAM-A), and morning fasting serum cortisol.

After 60 days, results in the Ashwagandha arm versus placebo:

• Serum cortisol — reduced by 27.9% in the Ashwagandha group versus 7.9% in the placebo group (P < 0.001)
• Perceived Stress Scale — reduced by 44% versus 5.5% (P < 0.0001)
• Hamilton Anxiety — reduced by 56.5% versus 30.5% (P < 0.0001)
• General Health Questionnaire — all four subscales (somatic, anxiety/insomnia, social dysfunction, depression) showed significant improvement
• Adverse events — mild and indistinguishable from placebo; one Ashwagandha subject reported nausea, one drowsiness, no withdrawals for adverse events

The magnitude of the cortisol reduction is what made the trial influential. A 28% drop in serum cortisol over 60 days is comparable to what is reported with cognitive behavioral therapy for chronic stress or with sustained mindfulness practice. The result was reproduced in a 2019 trial by Salve et al. using the same KSM-66 extract at a higher dose (600 mg/day for 8 weeks in 60 stressed adults), which found a 23% reduction in morning cortisol and a 32% reduction in PSS.

Back to Table of Contents

HPA-Axis Modulation and Cortisol Reduction

The hypothalamic-pituitary-adrenal (HPA) axis is the primary neuroendocrine system that translates psychological stress into circulating cortisol. The cascade begins when the hypothalamic paraventricular nucleus releases corticotropin-releasing hormone (CRH) in response to perceived threat. CRH stimulates the anterior pituitary to release adrenocorticotropic hormone (ACTH), which travels through circulation to the adrenal cortex and stimulates cortisol synthesis and release. Cortisol then exerts negative feedback at the hypothalamus and pituitary, theoretically closing the loop.

The problem in chronic psychological stress is that the negative feedback becomes blunted. Cortisol receptors in the hypothalamus and hippocampus are downregulated by sustained exposure, the loop fails to close efficiently, and morning cortisol levels rise out of the normal diurnal pattern. The downstream consequences include sleep disruption, abdominal adiposity, insulin resistance, hippocampal atrophy and impaired memory consolidation, suppressed gonadal axis with reduced testosterone in men and menstrual disruption in women, and immunosuppression.

Ashwagandha withanolides act at multiple points in this cascade. Animal studies have demonstrated reduced CRH release from the hypothalamus, reduced ACTH release from the pituitary, and direct dampening of adrenal cortisol synthesis. The integrated clinical effect — the 20-30% reduction in morning serum cortisol seen consistently across trials — emerges from this multi-level modulation rather than from any single receptor antagonism.

Importantly, the effect is not blunt suppression of all cortisol output. Ashwagandha does not appear to interfere with the normal acute stress response (the cortisol spike needed to deal with immediate physical or psychological threat). What it does is restore the diurnal rhythm and lower the elevated baseline that characterizes the chronic-stress state. This is a meaningful distinction from corticosteroid-suppressing medications.

Back to Table of Contents

GABA-A Receptor Modulation (Bhattacharya Foundation)

The acute anxiolytic effect of Ashwagandha — the calming felt within hours of a dose, before any HPA-axis remodeling has occurred — is mediated through positive allosteric modulation of the GABA-A receptor. This mechanism was established by Sushil Kumar Bhattacharya and colleagues at Banaras Hindu University in a series of papers in the late 1990s and early 2000s.

The GABA-A receptor is a pentameric ion channel that, when activated by the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), opens to allow chloride influx into neurons. This hyperpolarizes the cell and reduces its firing probability — the molecular basis of neural inhibition. The receptor has multiple modulatory binding sites distinct from the GABA binding site itself: benzodiazepines bind one site, barbiturates another, ethanol and neurosteroids yet others. Each of these positive allosteric modulators amplifies GABA's effect without directly opening the channel.

The Bhattacharya group demonstrated that the sitoindosides VII-X and withaferin A from Ashwagandha behave as GABA-A positive allosteric modulators, with effects most similar to those of neurosteroids (a milder, less sedating profile than benzodiazepines, no tolerance, no withdrawal). The behavioral correlate in rodent anxiety models (elevated plus maze, social interaction, open field) is an anxiolytic effect of magnitude comparable to a low dose of diazepam but without the motor incoordination or memory impairment.

This dual mechanism — acute GABAergic anxiolysis plus longer-term HPA-axis normalization — is what gives Ashwagandha its distinctive clinical profile. A first dose can produce a noticeable calming effect within 1-2 hours, while the more durable improvement in baseline anxiety scores typically emerges over 4-8 weeks as cortisol patterns normalize.

Back to Table of Contents

The Sensoril Full-Spectrum Trials

Sensoril (Natreon) is the second-most-studied standardized Ashwagandha extract after KSM-66. It is a full-spectrum extract derived from both roots and leaves, standardized to 10% withanolides (twice the withanolide content of KSM-66 on a per-gram basis), with the trade-off that it includes withaferin A from the leaves at meaningful concentration (KSM-66 has only trace withaferin A because it is root-only).

The Auddy 2008 trial — a 60-day double-blind randomized trial in 130 chronically stressed adults — tested Sensoril at 125 mg, 250 mg, and 500 mg per day versus placebo. All three doses produced significant reductions in serum cortisol, the Modified Hamilton Anxiety Scale, and the Perceived Stress Scale. The 500 mg dose produced the largest effect, with serum cortisol falling 32% from baseline. C-reactive protein, fasting blood glucose, total cholesterol, and triglycerides also improved in the high-dose arm.

The clinically relevant difference between Sensoril and KSM-66 is dosing — Sensoril is typically given at 125-250 mg total daily dose because of its higher withanolide concentration, while KSM-66 is typically given at 300-600 mg total daily dose. Both produce comparable anxiolytic and cortisol effects on a withanolide-adjusted basis. Some clinicians prefer Sensoril for acute anxiety and sleep applications because of its higher withaferin A content and demonstrated GABAergic potency, and prefer KSM-66 for testosterone and exercise outcomes because the most published RCT data on those endpoints uses KSM-66.

Back to Table of Contents

Application to Generalized Anxiety Disorder

Beyond the "stressed but otherwise well" population studied in Chandrasekhar and Auddy, Ashwagandha has been tested specifically in patients meeting DSM criteria for Generalized Anxiety Disorder (GAD). The Andrade 2000 trial in Indian Journal of Psychiatry randomized 39 GAD patients to either a withanolide-standardized Ashwagandha extract or placebo for 6 weeks. The Ashwagandha group showed a 56.5% reduction in Hamilton Anxiety scores versus 30.5% in placebo, with response rates (defined as >50% symptom reduction) of 88.2% versus 50%.

A 2009 trial by Cooley et al. published in PLOS ONE compared a comprehensive naturopathic protocol (including Ashwagandha at 300 mg twice daily, plus B-vitamin complex, calcium, magnesium, and lifestyle counseling) versus psychotherapy in 75 adults with moderate-to-severe anxiety. The naturopathic care arm produced superior improvement in Beck Anxiety Inventory scores at 12 weeks. The trial did not isolate the Ashwagandha contribution from the other interventions, but it documented that Ashwagandha-containing protocols can produce clinically meaningful improvement in measurable anxiety outcomes.

For patients with subclinical anxiety symptoms not meeting GAD criteria, Ashwagandha is often a first-line consideration in integrative practice because of its excellent safety profile and the absence of dependence or withdrawal that characterizes the benzodiazepine class. For diagnosed moderate-to-severe GAD, Ashwagandha is more commonly used as an adjunct to first-line pharmacotherapy and psychotherapy rather than as a sole intervention. See our Anxiety page for the broader management context.

Back to Table of Contents

Comparison with SSRIs, Benzodiazepines, and Buspirone

How does Ashwagandha compare against the conventional anxiolytic options? The honest answer is that head-to-head trials are scarce, so the comparison has to be made indirectly from separate trial literatures.

• Versus SSRIs (sertraline, escitalopram, paroxetine) — SSRIs produce response rates of approximately 50-60% in GAD at 8-12 weeks, with effect sizes (Hedges g) of about 0.36-0.45. Ashwagandha trial effect sizes range from approximately 0.6 to 1.0 (larger), but the trials are smaller, shorter, and largely industry-funded, so the apparent superiority may not survive larger independent replication. The clinical advantage of Ashwagandha is the side-effect profile — no sexual dysfunction, no GI upset, no activation/agitation in the first weeks, no discontinuation syndrome.
• Versus benzodiazepines (alprazolam, lorazepam, clonazepam) — benzodiazepines produce faster and stronger acute anxiolysis, but with tolerance, dependence, withdrawal risk, falls in the elderly, and cognitive impairment. Ashwagandha produces milder acute effect but no tolerance, no dependence, no cognitive impairment, and a far better long-term safety profile. For patients with chronic anxiety where benzodiazepines would be inappropriate (essentially everyone outside of acute panic or pre-procedural use), Ashwagandha is a reasonable substitute or adjunct.
• Versus buspirone — buspirone is a 5-HT1A partial agonist with anxiolytic effect of modest magnitude, slow onset (2-4 weeks), and good safety profile. The Ashwagandha clinical profile is most similar to buspirone — slower onset than benzodiazepines, no dependence, modest-to-moderate effect size. For patients who failed buspirone or want a non-prescription option with comparable risk-benefit, Ashwagandha is worth considering.
• Versus hydroxyzine — hydroxyzine is a first-generation antihistamine with anxiolytic properties, used short-term for situational anxiety. Ashwagandha lacks the sedating-antihistamine side effects (dry mouth, constipation, daytime grogginess) and is more appropriate for chronic daily use.

Back to Table of Contents

Dosing, Extract Type, and Timing

The clinical-trial-supported dosing depends on the extract:

• KSM-66 (root-only, 5% withanolides) — 300-600 mg per day, divided into two doses. The Chandrasekhar trial used 300 mg twice daily (600 mg total); the Wankhede testosterone trial used 600 mg per day; the Salve stress trial used 600 mg per day. Take with food to improve absorption of the fat-soluble withanolides.
• Sensoril (full-spectrum, 10% withanolides) — 125-500 mg per day, typically 250 mg once daily. The Auddy stress trial established efficacy down to 125 mg/day.
• Generic standardized extract (5% withanolides) — 600-1200 mg per day in divided doses, recognizing that batch-to-batch variability is much higher than with trial-grade extracts.
• Raw root powder (traditional preparation) — 3-6 grams per day, mixed in warm milk with a little ghee and honey (the classic kshirapaka preparation), or as a capsule. The traditional Ayurvedic dosing is higher because the raw powder contains a much lower percentage of active withanolides.

Timing is flexible — Ashwagandha is not strictly stimulating or sedating, and most people tolerate it morning or evening. For stress-and-anxiety applications, twice-daily dosing (morning and evening) provides smoother coverage than once-daily. For people who notice mild drowsiness, both doses can be moved later in the day; for those who notice mild alerting, both doses can be moved earlier. The evening dose is often kept even when the primary indication is daytime anxiety because the bedtime cortisol-lowering supports better sleep architecture.

Back to Table of Contents

Onset of Effect and Duration of Treatment

The acute GABAergic effect can be perceptible within 1-2 hours of the first dose — a subtle calming, slight reduction in racing thoughts, mild muscle-tension reduction. This is real pharmacology, not placebo, but its magnitude is much smaller than what a benzodiazepine produces acutely.

The clinically meaningful improvement in baseline anxiety, the cortisol reduction, and the durable change in stress reactivity emerges over 4-8 weeks. The Chandrasekhar trial measured at 60 days; the Auddy trial at 60 days; the Salve trial at 56 days. Patients should be counseled to give the supplement at least 6-8 weeks of consistent daily dosing before judging efficacy. People who try a week and conclude "it didn't work" are stopping before the dominant mechanism (HPA-axis remodeling) has had time to operate.

Duration of treatment is open-ended — trials have run as long as 16 weeks with maintained efficacy and no loss of effect. Ayurvedic tradition uses Ashwagandha as a daily rasayana for years at a time, and there is no published evidence of tolerance, dependence, or rebound on discontinuation. Some integrative practitioners cycle Ashwagandha (8 weeks on, 2 weeks off) on general principles for any chronic supplement, but the evidence base does not require cycling.

Back to Table of Contents

Stacking with L-Theanine, Magnesium, Rhodiola, and Holy Basil

Ashwagandha is commonly combined with other calming agents in integrative practice. Common pairings:

• L-theanine (200 mg, 1-3 times daily) — the amino acid from green tea that increases alpha-wave EEG activity and reduces anxiety without sedation. The two work through distinct mechanisms (Ashwagandha via GABA-A and HPA, L-theanine via NMDA modulation and brain-wave entrainment) and can be combined without overlap or interaction.
• Magnesium glycinate (200-400 mg elemental Mg, at bedtime) — magnesium is itself an NMDA antagonist and GABA-A modulator, and most stressed adults are mildly magnesium-deficient. The glycine moiety in glycinate is itself a calming inhibitory neurotransmitter.
• Rhodiola rosea (200-400 mg, mornings only) — an adaptogen with a complementary profile, more activating and cognitive-supportive than Ashwagandha. Common pattern: Rhodiola in the morning for energy and mental performance under stress, Ashwagandha later in the day and at bedtime for calming and sleep. See our Rhodiola Rosea page.
• Holy basil / tulsi (300-600 mg standardized, twice daily) — another Ayurvedic adaptogen with cortisol-lowering effect and complementary mild stimulant qualities. Often paired with Ashwagandha in traditional Ayurvedic formulas. See our Holy Basil page.
• Lemon balm (300-600 mg, as needed) — for acute situational anxiety, lemon balm extract is a GABA transaminase inhibitor with rapid onset. Pairs with the slower-building Ashwagandha effect. See our Lemon Balm page.
• Phosphatidylserine (100-300 mg) — a phospholipid that has been shown to blunt the cortisol response to acute exercise stress; sometimes combined with Ashwagandha for athletes or high-stress occupations.

Back to Table of Contents

Cautions and Contraindications

• Pregnancy — absolute contraindication. Withanolides have shown abortifacient activity in animal models, and Ayurvedic tradition has always proscribed Ashwagandha in pregnancy. Avoid during attempts to conceive in women if there is any concern about cycle disruption (Ashwagandha is fine for men trying to conceive — see the testosterone deep dive).
• Hyperthyroidism / Graves disease — Ashwagandha mildly upregulates thyroid hormone (T4 and T3) and can worsen hyperthyroidism or precipitate thyrotoxicosis in vulnerable patients. Use with caution and monitoring in anyone with treated hyperthyroidism, multinodular goiter, or subclinical hyperthyroidism. The thyroid-stimulating effect is generally beneficial in hypothyroid and subclinical-hypothyroid patients, but those individuals should still monitor TSH and free T4 if starting Ashwagandha.
• Autoimmune disease — Ashwagandha is mildly immunomodulatory and theoretically could exacerbate Th1-dominant autoimmune conditions (lupus, rheumatoid arthritis, multiple sclerosis, Hashimoto's thyroiditis). In practice, the clinical signal for this is weak, but use cautiously and watch for flares.
• Hepatotoxicity case reports — rare case reports of cholestatic hepatitis with Ashwagandha have appeared in the literature, mostly with unidentified extracts or self-reported contaminated products. The LiverTox database lists Ashwagandha as a "rare" cause of liver injury. Discontinue if abdominal pain, jaundice, or elevated LFTs occur, and check LFTs at baseline and periodically in patients on long-term high-dose use.
• Sedative interaction — the GABAergic mechanism creates a theoretical additive risk with benzodiazepines, alcohol, opioids, and other CNS depressants. Clinically the additive effect is mild but real — warn patients on combined therapy.
• Thyroid medication interaction — patients on levothyroxine should re-check TSH 6-8 weeks after starting Ashwagandha; some may need a dose reduction as endogenous thyroid output increases.
• Immunosuppressant interaction — theoretical antagonism with cyclosporine, tacrolimus, mycophenolate, and biologics for autoimmune disease. Avoid in transplant recipients.
• Nightshade family / allergy — Ashwagandha is a Solanaceae plant (related to tomato, potato, eggplant, pepper). True nightshade allergy is rare but a contraindication.

Back to Table of Contents

Key Research Papers

1. Chandrasekhar K, Kapoor J, Anishetty S (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. — PubMed
2. Auddy B, Hazra J, Mitra A, Abedon B, Ghosal S (2008). A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans. Journal of the American Nutraceutical Association. — PubMed
3. Salve J et al. (2019). Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus. — PubMed
4. Andrade C, Aswath A, Chaturvedi SK, Srinivasa M, Raguram R (2000). A double-blind, placebo-controlled evaluation of the anxiolytic efficacy of an ethanolic extract of Withania somnifera. Indian Journal of Psychiatry. — PubMed
5. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S (2000). Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine. — PubMed
6. Lopresti AL, Smith SJ, Malvi H, Kodgule R (2019). An investigation into the stress-relieving and pharmacological actions of an ashwagandha extract: a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). — PubMed
7. Cooley K et al. (2009). Naturopathic care for anxiety: a randomized controlled trial. PLOS ONE. — PubMed
8. Pratte MA, Nanavati KB, Young V, Morley CP (2014). An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha. Journal of Alternative and Complementary Medicine. — PubMed
9. Speers AB, Cabey KA, Soumyanath A, Wright KM (2021). Effects of Withania somnifera (ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia. Current Neuropharmacology. — PubMed
10. Mehta AK, Binkley P, Gandhi SS, Ticku MK (1991). Pharmacological effects of Withania somnifera root extract on GABA-A receptor complex. Indian Journal of Medical Research. — PubMed
11. Kumar V, Murthy KNC, Bhamid S, Sudha CG, Ravishankar GA (2015). Genetically modified hairy roots of Withania somnifera Dunal: a potent source of rejuvenating principles. Rejuvenation Research. — PubMed
12. Bonilla DA et al. (2021). Effects of ashwagandha (Withania somnifera) on physical performance: systematic review and bayesian meta-analysis. Journal of Functional Morphology and Kinesiology. — PubMed

PubMed Topic Searches

• PubMed: Ashwagandha cortisol RCTs
• PubMed: Withania anxiety/stress
• PubMed: Withanolide GABA mechanism
• PubMed: KSM-66 clinical trials
• PubMed: Sensoril stress trials
• PubMed: Ashwagandha HPA-axis
• PubMed: Ashwagandha and GAD
• PubMed: Ashwagandha chronic stress
• PubMed: Ashwagandha and depression
• PubMed: Ashwagandha safety
• PubMed: Ashwagandha hepatotoxicity
• PubMed: Ashwagandha and thyroid

Back to Table of Contents

Connections

• Ashwagandha Overview
• Ashwagandha Benefits Hub
• Ashwagandha for Sleep Quality
• Ashwagandha for Cognitive Function
• Ashwagandha for Testosterone
• Anxiety
• Depression
• PTSD
• Insomnia
• Stress Management
• Natural Anxiety Relief
• Rhodiola Rosea
• Holy Basil (Tulsi)
• Lemon Balm
• Bacopa Monnieri
• All Herbs

Back to Table of Contents